-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Sees Large Increase in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW) Sees Large Increase in Short Interest
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW – Get Rating) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 3,300 shares, a growth of 230.0% from the October 31st total of 1,000 shares. Based on an average daily volume of 9,600 shares, the short-interest ratio is currently 0.3 days.
Phoenix Biotech Acquisition Stock Performance
Shares of Phoenix Biotech Acquisition stock remained flat at $0.05 on Tuesday. The stock had a trading volume of 40,616 shares, compared to its average volume of 22,420. Phoenix Biotech Acquisition has a fifty-two week low of $0.02 and a fifty-two week high of $0.58. The business has a 50-day moving average price of $0.06 and a 200 day moving average price of $0.08.
Get Phoenix Biotech Acquisition alerts:Hedge Funds Weigh In On Phoenix Biotech Acquisition
Several institutional investors have recently added to or reduced their stakes in PBAXW. Context Capital Management LLC acquired a new position in Phoenix Biotech Acquisition in the 1st quarter valued at about $44,000. MMCAP International Inc. SPC increased its position in Phoenix Biotech Acquisition by 200.0% during the 1st quarter. MMCAP International Inc. SPC now owns 375,000 shares of the company's stock worth $82,000 after purchasing an additional 250,000 shares during the period. Clear Street LLC acquired a new position in Phoenix Biotech Acquisition during the 2nd quarter worth approximately $33,000. Finally, Periscope Capital Inc. increased its position in Phoenix Biotech Acquisition by 210.5% during the 3rd quarter. Periscope Capital Inc. now owns 930,798 shares of the company's stock worth $86,000 after purchasing an additional 630,998 shares during the period.
Phoenix Biotech Acquisition Company Profile
(Get Rating)Phoenix Biotech Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. It focuses on pursuing opportunities in the life sciences sector. The company was incorporated in 2021 and is based in Oakland, California.
See Also
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAXW)
- Three Reasons It's Time To Get Bullish On Organigram
- Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
- Why Investors Are Eating Up Restaurant Brands International
- Zoom Video Continues to Work Through Normalization
- What an Inverted Yield Curve Means for Investors
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXW – Get Rating) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 3,300 shares, a growth of 230.0% from the October 31st total of 1,000 shares. Based on an average daily volume of 9,600 shares, the short-interest ratio is currently 0.3 days.
鳳凰生物科技收購公司(納斯達克代碼:PBAXW-GET評級)是空頭股數11月份大幅增長的目標。截至15日,空頭股數共有3,300股,較10月31日的1,000股增長了230.0%。以日均成交量9,600股計算,短息比率目前為0.3天。
Phoenix Biotech Acquisition Stock Performance
鳳凰生物科技收購股票表現
Shares of Phoenix Biotech Acquisition stock remained flat at $0.05 on Tuesday. The stock had a trading volume of 40,616 shares, compared to its average volume of 22,420. Phoenix Biotech Acquisition has a fifty-two week low of $0.02 and a fifty-two week high of $0.58. The business has a 50-day moving average price of $0.06 and a 200 day moving average price of $0.08.
週二,鳳凰生物科技收購股票的股價持平於0.05美元。該股成交量為40,616股,而其平均成交量為22,420股。鳳凰生物科技的收購價格為52周低點0.02美元和52周高點0.58美元。該業務的50日移動均線價格為0.06美元,200日移動均線價格為0.08美元。
Hedge Funds Weigh In On Phoenix Biotech Acquisition
對衝基金參與鳳凰生物科技的收購
Several institutional investors have recently added to or reduced their stakes in PBAXW. Context Capital Management LLC acquired a new position in Phoenix Biotech Acquisition in the 1st quarter valued at about $44,000. MMCAP International Inc. SPC increased its position in Phoenix Biotech Acquisition by 200.0% during the 1st quarter. MMCAP International Inc. SPC now owns 375,000 shares of the company's stock worth $82,000 after purchasing an additional 250,000 shares during the period. Clear Street LLC acquired a new position in Phoenix Biotech Acquisition during the 2nd quarter worth approximately $33,000. Finally, Periscope Capital Inc. increased its position in Phoenix Biotech Acquisition by 210.5% during the 3rd quarter. Periscope Capital Inc. now owns 930,798 shares of the company's stock worth $86,000 after purchasing an additional 630,998 shares during the period.
幾家機構投資者最近增持或減持了PBAXW的股份。Context Capital Management LLC在第一季度收購了菲尼克斯生物技術公司的一個新頭寸,價值約4.4萬美元。MMPCAP國際公司在第一季度將其在菲尼克斯生物技術公司收購中的地位增加了200.0%。MmCap International Inc.SPC現在持有375,000股該公司股票,價值82,000美元,在此期間又購買了250,000股。Clear Street LLC在第二季度收購了菲尼克斯生物技術公司,價值約3.3萬美元。最後,Periscope Capital Inc.在第三季度將其在菲尼克斯生物技術公司收購中的頭寸增加了210.5%。Periscope Capital Inc.在此期間又購買了630,998股,目前持有930,798股該公司股票,價值86,000美元。
Phoenix Biotech Acquisition Company Profile
鳳凰生物科技收購公司簡介
Phoenix Biotech Acquisition Corp. intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. It focuses on pursuing opportunities in the life sciences sector. The company was incorporated in 2021 and is based in Oakland, California.
菲尼克斯生物技術收購公司打算通過合併、股份交換、股份購買、重組或類似的業務合併來收購資產和業務。它專注於在生命科學領域尋找機會。該公司成立於2021年,總部設在加利福尼亞州奧克蘭。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAXW)
- Three Reasons It's Time To Get Bullish On Organigram
- Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
- Why Investors Are Eating Up Restaurant Brands International
- Zoom Video Continues to Work Through Normalization
- What an Inverted Yield Curve Means for Investors
- 免費獲取StockNews.com關於鳳凰生物科技收購的研究報告(PBAXW)
- 看好Organigram的三個原因
- 機遇來了!Hibbett,Inc.業績強勁,股價持平
- 為什麼投資者正在吞併餐飲品牌國際公司
- 通過標準化,Zoom Video繼續發揮作用
- 收益率曲線倒置對投資者意味着什麼
Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《鳳凰生物科技收購日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對菲尼克斯生物技術收購和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧